{
  "title": "Paper_833",
  "abstract": "pmc Nutrients Nutrients 1692 nutrients nutrients Nutrients 2072-6643 Multidisciplinary Digital Publishing Institute  (MDPI) PMC12472629 PMC12472629.1 12472629 12472629 41010480 10.3390/nu17182952 nutrients-17-02952 1 Article Survival and Impact on Microbial Diversity of Lacticaseibacillus paracasei https://orcid.org/0009-0005-8720-1255 Duysburgh Cindy 1 https://orcid.org/0009-0005-2423-0016 Fiore Walter 2 * Marzorati Massimo 1 3 Wang Minqi Academic Editor 1 2 3 * walter.fiore@alfasigma.com 13 9 2025 9 2025 17 18 497660 2952 31 7 2025 03 9 2025 10 9 2025 13 09 2025 27 09 2025 29 09 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ Background/Objectives: Lacticaseibacillus paracasei Methods: ® Results: Escherichia coli Blautia wexlerae Conclusions: Lacticaseibacillus paracasei probiotics SHIME survival metabolic activity colonic microbial diversity Alfasigma S.p.A., Bologna, Italy This research was funded by Alfasigma S.p.A., Bologna, Italy. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes 1. Introduction Probiotic treatments can help to improve lower gastrointestinal (GI) symptoms, as shown by Delphi consensus statements [ 1 2 Lactobacillus Lactobacillus 3 4 Lacticaseibacillus 3 Lacticaseibacillus paracasei (L. paracasei) ® ® Lactobacillus paracasei 3 5 6 L. paracasei 7 8 Helicobacter pylori 9 10 11 12 Clinical trials can only provide information on input and output of the probiotic, and the mechanism by which L. paracasei 13 14 13 15 Intake of L. paracasei Coprococcus Blautia 16 17 18 18 In vitro models simulating the physiological conditions of the complete upper GI tract allow for sampling of the intestinal microbial community from each region of the tract, without the need for invasive methods, to provide in-depth mechanistic insights into the mode of action of probiotics [ 17 ® 17 19 This study employed a modified version of the SHIME ® L. paracasei L. paracasei 2. Materials and Methods 2.1. Composition of Capsule Systems L. paracasei L. paracasei 2.2. Modified In Vitro SHIME ® A modified SHIME ® 19 Supplementary Figure S1 20 21 22 Figure 1 Figure 1 22 23 2.3. Simulated Stomach and Small Intestinal Digestions For the fed condition, stomach digestion was simulated by the incubation of simulated gastric fluid (SHIME ® Salt levels were in accordance with those in the European Cooperation in Science and Technology Action InfoGest consensus methods [ 21 Figure 1 For the fed condition, the simulated gastric fluid was combined with raw animal pancreatic extract containing all relevant enzymes and 10 mM bovine extract, as previously described [ 20 22 Figure 1 The tests were conducted similarly for the fasted and shortened fasted conditions, with the following modifications [ 22 The ‘shortened fasted’ condition was included to represent an intermediate state between fed and fasted states, and to account for the variability in gastric emptying times and luminal conditions between individuals and circumstances. For the shortened fasted condition, the incubation time for the ST was 10 min (compared with 45 min for the fasted condition). Modifications to the pH and concentrations of pepsin and phosphatidylcholine were the same as for the fasted condition. The small intestinal digestion times were shortened from the fasted condition to 13.5 min (DUO), 31.5 min (JEJ), and 45 min (ILE). Sampling and visual scoring were conducted at baseline, at the end of the ST phase, and after each small intestinal phase. 2.4. Visual Assessment of Capsule Integrity Visual assessment of the capsule integrity was conducted before digestion (unprocessed product) and at the end of each simulated phase of the upper GI tract (ST end, DUO end, JEJ end, and ILE end). Capsule integrity was classified as follows: (1) intact capsule, no product released; (2) capsule damaged but almost all product is still in the capsule; (3) capsule damaged and all product released; and (4) capsule destroyed and all product released. 2.5. Quantification of CFU L. paracasei 2.6. Quantification of Viable and Non-Viable Bacterial Cells by Flow Cytometry Samples collected at the start and at the ends of the ST, DUO, JEJ, and ILE phases were assessed by SYTO 24 and propidium iodide staining. Samples were analysed using a BD FACSVerse (BD Biosciences, Franklin Lake, NJ, USA). 2.7. Short-Term Colonic Incubation Experiments Colonic incubations were performed for encapsulated L. paracasei ® 2.8. Microbial Metabolic Activity Microbial metabolic activity was assessed at 0 h and 24 h of incubation as previously described [ 20 L. paracasei 2.9. Microbial Community Composition L. paracasei ® Supplementary Figure S2 L. paracasei Shallow shotgun sequencing was performed to evaluate the modulation of the microbial composition upon exposure to L. paracasei ® 24 25 2.10. Data Analysis For the endpoints of the upper GI tract simulation, two-tailed paired Student’s t t p 3. Results 3.1. Capsule Integrity and Survival of L. paracasei DG Under Fed, Fasted, and Shortened Fasted Conditions The durability of the capsule and subsequent survival of encapsulated L. paracasei Figure 2 Figure 2 L. paracasei Figure 2 L. paracasei Figure 2 Under fasted conditions, the capsule was damaged at ST end (visual score: 2) and was fully degraded by ILE end (visual score: 4; Figure 2 Figure 2 L. paracasei Under shortened fasted conditions, the capsule was intact at ST end and was fully digested by ILE end (visual score: 4; Figure 2 L. paracasei L. paracasei L. paracasei Figure 2 3.2. Microbial Fermentation of Human Faecal Inoculum Following the Administration of L. paracasei DG In a blank colonic control incubation with healthy human faecal inoculum for 24 h, the pH changed from baseline by between –0.34 and –0.29 across the fed, fasted, and shortened fasted conditions ( Figure 3 L. paracasei p Figure 3 L. paracasei To assess microbial metabolic activity further, the changes in lactate and SCFA concentrations were quantified ( Figure 4 Figure 4 L. paracasei p Figure 4 L. paracasei p p Figure 4 L. paracasei p Figure 4 L. paracasei p Figure 4 3.3. Quantification of L. paracasei DG Following 24 h of Colonic Incubation Quantification of the 16S ribosomal RNA gene copies/mL in the blank control incubation showed no detectable L. paracasei Figure 5 L. paracasei 7 8 3.4. Composition of the Donor Microbial Community Following L. paracasei DG Incubation Analysis of the donor microbial community through shallow shotgun sequencing demonstrated that similar microbial diversity was observed for all test conditions at the start of the incubation ( Table 1 L. paracasei The impact of supplementation with L. paracasei Supplementary Table S1 Supplementary Table S2 Table 2 Supplementary Table S1 L paracasei p Several microbial communities were affected by L. paracasei Escherichia coli L. paracasei Table 2 Blautia wexlerae L. paracasei Under fed conditions, treatment with L. paracasei Supplementary Table S2 Dorea longicatena Agathobacter rectalis Eubacterium rectale Table 2 L. paracasei L. paracasei p Supplementary Table S2 L. paracasei p L. paracasei L. paracasei Supplementary Table S2 Ruminococcus L. paracasei Table 2 Faecalibacterium prausnitzii 4. Discussion To provide mechanistic insight on the reported benefits observed for volunteers and patients receiving supplemental L. paracasei 9 10 11 26 L. paracasei ® L. paracasei 14 L. paracasei L. paracasei 5 6 The main process occurring in the colon is microbial fermentation, which is due to the beneficial pH conditions and the constant provision to the gut flora of dietary non-digestible carbohydrates, host-derived glycans, and proteins [ 27 28 29 L. paracasei 30 31 32 L. paracasei 9 Decreased lactate concentrations may appear initially counterintuitive because lactobacilli are one of the main producers of lactate [ 33 L. paracasei L. paracasei Blautia wexlerae L. paracasei Similar SHIME ® Lactobacillus L. acidophilus, L. rhamnosus, L. helveticus 34 35 36 37 L. acidophilus L. paracasei 34 L. paracasei Heyndrickxia coagulans 20 36 L. paracasei 38 L. acidophilus 20 A key strength of this study was the use of the modified SHIME ® ® L. paracasei L. paracasei L. paracasei L. paracasei L. paracasei 5. Conclusions The viability and culturability of L. paracasei L. paracasei L. paracasei L. paracasei L. paracasei Acknowledgments Medical writing support was provided by Annika Pecchia-Bekkum, PhD, of PharmaGenesis London, London, UK, and was funded by Alfasigma S.p.A. Disclaimer/Publisher’s Note: Supplementary Materials The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/nu17182952/s1 ® L. paracasei Author Contributions Conceptualization, C.D., W.F., and M.M.; methodology, C.D., W.F., and M.M.; software, C.D. and M.M.; validation, C.D. and M.M.; formal analysis, C.D. and M.M.; investigation, C.D. and M.M.; visualization, C.D. and M.M.; data curation, C.D. and M.M.; writing—review and editing, C.D., W.F., and M.M. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement Not applicable. Informed Consent Statement Not applicable. Data Availability Statement The data presented in this study are available on request from the corresponding author due to the proprietary nature of the methods used. Conflicts of Interest C.D. is employed by ProDigest. WF is employed by Alfasigma S.p.A. M.M. is employed by ProDigest and is a voluntary visiting professor at the University of Ghent (of which, ProDigest is a spin-off company). The authors declare the role of ProDigest was data analysis and that this study received funding and medical writing support funding from Alfasigma S.p.A. The development of the manuscript and the decision to submit this manuscript was solely the decision of the authors. All authors have read and agreed to the published version of the manuscript. Abbreviations The following abbreviations are used in this manuscript: BCFA Branched-chain fatty acid CFU Colony-forming units DUO Duodenum GI Gastrointestinal ILE Ileum IBS Irritable bowel syndrome JEJ Jejunum PCR Polymerase chain reaction SCFA Short-chain fatty acid SHIME Simulator of the Human Intestinal Microbial Ecosystem SD Standard deviation Sp. Species ST Stomach SUDD Symptomatic uncomplicated diverticular disease u_f unclassified family References 1. Hungin A.P. Mulligan C. Pot B. Whorwell P. Agreus L. Fracasso P. Lionis C. Mendive J. Philippart de Foy J.M. Rubin G. Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice—An evidence-based international guide Aliment. Pharmacol. Ther. 2013 38 864 886 10.1111/apt.12460 23981066 PMC3925990 2. Hungin A.P.S. Mitchell C.R. Whorwell P. Mulligan C. Cole O. Agreus L. Fracasso P. Lionis C. Mendive J. Philippart de Foy J.M. Systematic review: Probiotics in the management of lower gastrointestinal symptoms—An updated evidence-based international consensus Aliment. Pharmacol. Ther. 2018 47 1054 1070 10.1111/apt.14539 29460487 PMC5900870 3. Zheng J. Wittouck S. Salvetti E. Franz C. Harris H.M.B. Mattarelli P. O’Toole P.W. Pot B. Vandamme P. Walter J. A taxonomic note on the genus Lactobacillus Lactobacillus Lactobacillaceae Leuconostocaceae Int. J. Syst. Evol. Microbiol. 2020 70 2782 2858 10.1099/ijsem.0.004107 32293557 4. Cichonska P. Ziarno M. Legumes and legume-based beverages fermented with lactic acid bacteria as a potential carrier of probiotics and prebiotics Microorganisms 2021 10 91 10.3390/microorganisms10010091 35056540 PMC8779895 5. Arioli S. Koirala R. Taverniti V. Fiore W. Guglielmetti S. Quantitative recovery of viable Lactobacillus paracasei L. casei ® Front. Microbiol. 2018 9 1720 10.3389/fmicb.2018.01720 30116228 PMC6083036 6. Radicioni M. Koirala R. Fiore W. Leuratti C. Guglielmetti S. Arioli S. Survival of L. casei ® Lactobacillus paracasei Eur. J. Nutr. 2019 58 3161 3170 10.1007/s00394-018-1860-5 30498868 PMC6842349 7. Tursi A. Brandimarte G. Giorgetti G.M. Elisei W. Mesalazine and/or Lactobacillus casei J. Clin. Gastroenterol. 2006 40 312 316 10.1097/01.mcg.0000210092.77296.6d 16633103 8. Tursi A. Brandimarte G. Giorgetti G.M. Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon Hepatogastroenterology 2008 55 916 920 18705297 9. Cremon C. Guglielmetti S. Gargari G. Taverniti V. Castellazzi A.M. Valsecchi C. Tagliacarne C. Fiore W. Bellini M. Bertani L. Effect of Lactobacillus paracasei United Eur. Gastroenterol. J. 2018 6 604 613 10.1177/2050640617736478 PMC5987284 29881616 10. D’Inca R. Barollo M. Scarpa M. Grillo A.R. Brun P. Vettorato M.G. Castagliuolo I. Sturniolo G.C. Rectal administration of Lactobacillus casei Dig. Dis. Sci. 2011 56 1178 1187 10.1007/s10620-010-1384-1 20737210 11. Tursi A. Brandimarte G. Giorgetti G.M. Modeo M.E. Effect of Lactobacillus casei Helicobacter pylori Med. Sci. Monit. 2004 10 CR662-666 15567983 12. Gargari G. Mantegazza G. Cremon C. Taverniti V. Valenza A. Barbaro M.R. Marasco G. Duncan R. Fiore W. Ferrari R. Collinsella aerofaciens Gut Microbes 2024 16 2298246 10.1080/19490976.2023.2298246 38178601 PMC10773624 13. Sarita B. Samadhan D. Hassan M.Z. Kovaleva E.G. A comprehensive review of probiotics and human health-current prospective and applications Front. Microbiol. 2024 15 1487641 10.3389/fmicb.2024.1487641 39834364 PMC11743475 14. Han S. Lu Y. Xie J. Fei Y. Zheng G. Wang Z. Liu J. Lv L. Ling Z. Berglund B. Probiotic gastrointestinal transit and colonization after oral administration: A long journey Front. Cell Infect. Microbiol. 2021 11 609722 10.3389/fcimb.2021.609722 33791234 PMC8006270 15. Albertini B. Vitali B. Passerini N. Cruciani F. Di Sabatino M. Rodriguez L. Brigidi P. Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus Bifidobacterium lactis Eur. J. Pharm. Sci. 2010 40 359 366 10.1016/j.ejps.2010.04.011 20420903 16. Ferrario C. Taverniti V. Milani C. Fiore W. Laureati M. De Noni I. Stuknyte M. Chouaia B. Riso P. Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei J. Nutr. 2014 144 1787 1796 10.3945/jn.114.197723 25332478 17. Zhu W. Zhang X. Wang D. Yao Q. Ma G.L. Fan X. Simulator of the Human Intestinal Microbial Ecosystem (SHIME ® Pharmaceuticals 2024 17 1639 10.3390/ph17121639 39770481 PMC11677124 18. Park J.C. Im S.H. Of men in mice: The development and application of a humanized gnotobiotic mouse model for microbiome therapeutics Exp. Mol. Med. 2020 52 1383 1396 10.1038/s12276-020-0473-2 32908211 PMC8080820 19. Molly K. Vande Woestyne M. Verstraete W. Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem Appl. Microbiol. Biotechnol. 1993 39 254 258 10.1007/BF00228615 7763732 20. Marzorati M. Calatayud M. Rotsaert C. Van Mele M. Duysburgh C. Durkee S. White T. Fowler K. Jannin V. Bellamine A. Comparison of protection and release behavior of different capsule polymer combinations based on L. acidophilus Int. J. Pharm. 2021 607 120977 10.1016/j.ijpharm.2021.120977 34384885 21. Mackie A. Rigby N. InfoGest Consensus Method The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models Verhoeckx K. Cotter P. López-Expósito I. Kleiveland C. Lea T. Mackie A. Requena T. Swiatecka D. Wichers H. Springer Cham, Switzerland 2015 Chapter 2 13 22 10.1007/978-3-319-16104-4_2 29787039 22. Riethorst D. Mols R. Duchateau G. Tack J. Brouwers J. Augustijns P. Characterization of human duodenal fluids in fasted and fed state conditions J. Pharm. Sci. 2016 105 673 681 10.1002/jps.24603 26228456 23. Mudie D.M. Amidon G.L. Amidon G.E. Physiological parameters for oral delivery and in vitro testing Mol. Pharm. 2010 7 1388 1405 10.1021/mp100149j 20822152 PMC3025274 24. Hasan N.A. Young B.A. Minard-Smith A.T. Saeed K. Li H. Heizer E.M. McMillan N.J. Isom R. Abdullah A.S. Bornman D.M. Microbial community profiling of human saliva using shotgun metagenomic sequencing PLoS ONE 2014 9 e97699 10.1371/journal.pone.0097699 24846174 PMC4028220 25. Lax S. Smith D.P. Hampton-Marcell J. Owens S.M. Handley K.M. Scott N.M. Gibbons S.M. Larsen P. Shogan B.D. Weiss S. Longitudinal analysis of microbial interaction between humans and the indoor environment Science 2014 345 1048 1052 10.1126/science.1254529 25170151 PMC4337996 26. Bretto E. D’Amico F. Fiore W. Tursi A. Danese S. Lactobacillus paracasei J. Clin. Med. 2022 11 1916 10.3390/jcm11071916 35407527 PMC8999804 27. Lee J.Y. Tsolis R.M. Baumler A.J. The microbiome and gut homeostasis Science 2022 377 eabp9960 10.1126/science.abp9960 35771903 28. Koropatkin N.M. Cameron E.A. Martens E.C. How glycan metabolism shapes the human gut microbiota Nat. Rev. Microbiol. 2012 10 323 335 10.1038/nrmicro2746 22491358 PMC4005082 29. Mutuyemungu E. Singh M. Liu S. Rose D.J. Intestinal gas production by the gut microbiota: A review J. Funct. Foods 2023 100 105367 10.1016/j.jff.2022.105367 30. Singh V. Lee G. Son H. Koh H. Kim E.S. Unno T. Shin J.H. Butyrate producers, “The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics Front. Microbiol. 2022 13 1103836 10.3389/fmicb.2022.1103836 36713166 PMC9877435 31. Li G. Lin J. Zhang C. Gao H. Lu H. Gao X. Zhu R. Li Z. Li M. Liu Z. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease Gut Microbes 2021 13 1968257 10.1080/19490976.2021.1968257 34494943 PMC8437544 32. Kaźmierczak-Siedlecka K. Marano L. Merola E. Roviello F. Połom K. Sodium butyrate in both prevention and supportive treatment of colorectal cancer Front. Cell Infect. Microbiol. 2022 12 1023806 10.3389/fcimb.2022.1023806 36389140 PMC9643746 33. Moens F. Verce M. De Vuyst L. Lactate- and acetate-based cross-feeding interactions between selected strains of lactobacilli, bifidobacteria and colon bacteria in the presence of inulin-type fructans Int. J. Food Microbiol. 2017 241 225 236 10.1016/j.ijfoodmicro.2016.10.019 27810444 34. Sivieri K. Morales M.L. Adorno M.A. Sakamoto I.K. Saad S.M. Rossi E.A. Lactobacillus acidophilus BMC Gastroenterol. 2013 13 100 10.1186/1471-230X-13-100 23758634 PMC3700768 35. Liu L. Narrowe A.B. Firrman J.A. Mahalak K.K. Bobokalonov J.T. Lemons J.M.S. Bittinger K. Daniel S. Tanes C. Mattei L. Lacticaseibacillus rhamnosus Foods 2023 12 2105 10.3390/foods12112105 37297350 PMC10252382 36. Goya-Jorge E. Gonza I. Bondue P. Druart G. Al-Chihab M. Boutaleb S. Douny C. Taminiau B. Daube G. Scippo M.L. Unveiling the influence of a probiotic combination of Heyndrickxia coagulans Lacticaseibacillus casei ® Microbiol. Res. 2024 285 127778 10.1016/j.micres.2024.127778 38823185 37. De Oliveira F.L. Salgaço M.K. de Oliveira M.T. Mesa V. Sartoratto A. Peregrino A.M. Ramos W.S. Sivieri K. Exploring the potential of Lactobacillus helveticus Bifidobacterium longum Nutrients 2023 15 1521 10.3390/nu15061521 36986251 PMC10056475 38. Verbeke K.A. Boobis A.R. Chiodini A. Edwards C.A. Franck A. Kleerebezem M. Nauta A. Raes J. van Tol E.A. Tuohy K.M. Towards microbial fermentation metabolites as markers for health benefits of prebiotics Nutr. Res. Rev. 2015 28 42 66 10.1017/S0954422415000037 26156216 PMC4501371 Figure 1 pH profiles for fed ( A B Figure 2 Capsule integrity and survival of L. paracasei ® n A C E n B D F L. paracasei L. paracasei L. paracasei p Figure 3 Overall microbial metabolic activity in short colonic incubations. Change (mean [SD]) in pH ( A B L. paracasei n p Figure 4 Microbial metabolic activity in short colonic incubations. Change (mean [SD]) in total lactic acid ( A B C D E L. paracasei n p Figure 5 Quantitative PCR enumeration of L. paracasei L. paracasei L. paracasei n p nutrients-17-02952-t001_Table 1 Table 1 Reciprocal Simpson’s index.  Fed Fasted Short Fasted  Blank L. paracasei Blank L. paracasei Blank L. paracasei 0 h 25.7 26.2 24.7 24.3 26.6 26.8 24 h 6.0 7.2 18.6 16.4 14.7 14.4 The reciprocal Simpson’s index in colonic incubations at baseline (0 h) and after 24 h in the presence of encapsulated L. paracasei n n nutrients-17-02952-t002_Table 2 Table 2 Average relative abundance of the top 25 most abundant and relevant bacterial species at 0 h and 24 h after colonic incubation. Phylum Family Species 0 h Fed Fasted Shortened Fasted Blank (%) L. paracasei Blank (%) L. paracasei Blank (%) L. paracasei Actinobacteria Bifidobacteriaceae  Bifidobacterium adolescentis 11.5 11.7 11.9 11.9 9.8 9.6  Bifidobacterium longum 1.3 1.2 1.3 1.2 1.1 1.0  Bifidobacterium sp. 12_1_47BFAA 1.5 1.4 1.4 0.9 1.3 0.9 Coriobacteriaceae  Collinsella aerofaciens 2.4 2.4 2.8 2.7 2.1 2.1  Collinsella sp. 4_8_47FAA 2.6 2.6 3.1 3.0 2.3 2.3  Senegalimassilia anaerobia 0.3 0.3 0.3 0.3 0.3 0.3 Bacteroidetes Bacteroidaceae  Bacteroides coprocola 5.9 6.1 6.9 7.2 8.0 7.4  Bacteroides dorei 1.4 1.4 1.5 1.6 2.0 1.5  Bacteroides thetaiotaomicron 0.4 0.4 0.5 0.5 0.5  0.5  Bacteroides vulgatus 4.1 4.0 4.3 4.6 4.6 4.5  Bacteroides sp. 3_1_40A 2.4 3.6 1.4 2.8 4.2 2.6  Bacteroides sp. 4_3_47FAA 1.3 0.0 2.5 1.5 0.0 1.5 Rikenellaceae  Alistipes putredinis 5.0  4.5 5.0 5.0 4.8 5.0 Firmicutes Acidaminococcaceae  Phascolarctobacterium succinatutens 2.4 2.1 2.2 1.9 2.0 2.0 Bacillaceae  Bacillus clausii 0.0 0.0 0.0 0.0 0.0 0.0 Clostridiaceae  Clostridium sp. L2-50 4.3 4.2 4.0 3.4 4.2 4.2 Lachnospiraceae  Blautia wexlerae 1.9 1.8 1.9 1.7 2.0 2.0  Dorea longicatena 1.2 1.1 0.9 0.8 1.1  1.0  Agathobacter rectalis 3.8 3.4 3.5 3.1 3.9 4.0 Lactobacillaceae  Lactobacillus paracasei 0.0  4.4 0.0  4.3 0.0  4.8 Ruminococcaceae  Faecalibacterium prausnitzii 5.8 5.2 5.6 5.3 4.7 4.8  Ruminococcus bromii 6.0 5.2 5.9 5.5 6.1  5.4  Ruminococcus sp. 5_1_39BFAA 2.2 2.1 2.2 2.0 2.4 2.3 Proteobacteria Enterobacteriaceae  Escherichia coli 0.0 0.1 0.0 0.0 0.1 0.1 Sutterellaceae  Sutterella wadsworthensis 0.9 0.8 0.5 0.6 0.8 0.8   24 h Actinobacteria Bifidobacteriaceae  Bifidobacterium adolescentis 38.8 35.3 19.5 21.6 23.2 23.7  Bifidobacterium longum 2.9 2.8 2.0  2.5 2.4 2.5  Bifidobacterium sp. 12_1_47BFAA 3.3 3.3 1.5 2.8 2.7 2.9 Coriobacteriaceae  Collinsella aerofaciens 1.0 1.0 2.7 2.3 1.6  1.3  Collinsella sp. 4_8_47FAA 1.2 1.2 3.0 2.6 1.8  1.5  Senegalimassilia anaerobia 2.7  2.2 3.6 3.2 3.3 2.8 Bacteroidetes Bacteroidaceae  Bacteroides coprocola 0.0 0.0 0.1 0.1 0.1 0.1  Bacteroides dorei 1.0 1.0 1.6 1.4 1.7 1.6  Bacteroides thetaiotaomicron 1.5 1.3 2.8 2.4 2.2 1.8  Bacteroides vulgatus 2.4 2.3 3.0 3.5 3.4 3.6  Bacteroides sp. 3_1_40A 0.0 0.0 0.0 0.0 0.0 0.0  Bacteroides sp. 4_3_47FAA 2.2 2.1 2.8 3.1 3.1 3.3 Rikenellaceae  Alistipes putredinis 0.7 0.6 1.2 1.2 1.4 1.6 Firmicutes Acidaminococcaceae  Phascolarctobacterium succinatutens 0.8 0.7 1.2 1.0 1.4  1.2 Bacillaceae  Bacillus clausii 0.0 0.0 0.0 0.0 0.0 0.0 Clostridiaceae  Clostridium sp. L2-50 0.4 0.0 0.4 0.0 0.0 0.0 Lachnospiraceae  Blautia wexlerae 1.6  1.3 1.9  1.2 2.5  1.4  Dorea longicatena 0.7  1.0 2.8 2.7 1.0 0.9  Agathobacter rectalis 0.6  0.8 1.9 1.6 1.2 1.5 Lactobacillaceae  Lactobacillus paracasei 0.0  3.7 0.0  3.6 0.0  4.5 Ruminococcaceae  Faecalibacterium prausnitzii 0.8 1.0 1.4 1.3 1.9 1.8  Ruminococcus bromii 1.6 1.7 3.0 2.3 3.2 2.6  Ruminococcus sp. 5_1_39BFAA 1.9 1.6 2.3  1.5 3.0  1.7 Proteobacteria Enterobacteriaceae  Escherichia coli 10.4  7.7 5.0  3.9 6.0  4.5 Sutterellaceae  Sutterella wadsworthensis 1.6 1.9 3.0 2.4 1.0 1.2 Average relative abundance of the top 25 bacterial species in colonic incubation at baseline (0 h) and after 24 h in the presence of encapsulated L. paracasei n n p ",
  "metadata": {
    "Title of this paper": "Towards microbial fermentation metabolites as markers for health benefits of prebiotics",
    "Journal it was published in:": "Nutrients",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472629/"
  }
}